CONTROL OF SENSOR/TISSUE INTERACT FOR EXTENDED LIFETIME

控制传感器/组织相互作用以延长使用寿命

• 批准号: 6188687
• 负责人: FRANCIS MOUSSY
• 金额: $ 38.45万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2002-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6188687
• 关键词: artificial membranes; bioengineering /biomedical engineering; biological response modifiers; biomaterial development /preparation; biomaterial evaluation; biomaterial interface interaction; biosensor device; blood glucose; copolymer; diabetes mellitus; gel; laboratory rat; microcapsule; microdialysis; monitoring device

DESCRIPTION (Adapted from applicant's abstract): A major obstacle to the wide application of implantable glucose sensors is that the progressively lose function after a relatively short period of time in vivo. This is a result of tissue responses such as inflammation and fibrosis with resulting loss of vasculature as well as degradation of the sensor. Although our current Nafion-based glucose sensor displayed excellent stability in vitro, it rapidly calcified and degraded in vivo. The investigator hypothesizes that in vivo sensor performance can be enhanced by developing new membranes and by controlling the tissue interface by suppressing inflammation and fibrosis as well as increasing neovascularization. Aim 1 will develop new membranes to replace Nafion, and also to develop novel surface hydrogels with tissue response modifiers (TRM's) to control fibrosis, inflammation, and neovascularization. Aim 2 will develop biodegradable TRM delivery systems to control inflammation, fibrosis and neovascularization. Aim 3 will evaluate in vitro and in vivo (rats), the developed sensors and components to determine performance, including life span.

描述（改编自申请人的摘要）： 植入式葡萄糖传感器的广泛应用是 在体内相对较短的时间内失去功能。 这是一个 炎症和纤维化等组织反应的结果 脉管系统损失以及传感器退化。 虽然我们的 目前基于 Nafion 的葡萄糖传感器在体外表现出优异的稳定性， 它在体内迅速钙化和降解。 研究者假设 通过开发新的膜可以增强体内传感器的性能 并通过抑制炎症和控制组织界面 纤维化以及新血管形成增加。 目标1将开发新的 膜取代 Nafion，并开发新型表面水凝胶 使用组织反应调节剂 (TRM) 来控制纤维化、炎症、 和新生血管形成。 目标 2 将开发可生物降解的 TRM 递送 控制炎症、纤维化和新血管形成的系统。 目标 3 将在体外和体内（大鼠）评估开发的传感器和 组件来确定性能，包括使用寿命。